H1 Results: a strong first half of 2025 

The first six months of 2025 have been exceptional for Ipsen. We’ve delivered strong growth across all three of our therapeutic areas — Rare Disease, Oncology, and Neuroscience — reflecting the strength of our strategy and the dedication of our teams. 

We’ve also made remarkable progress in our pipeline and portfolio, with new approvals and promising assets advancing into clinical development. These milestones are a testament to our continued focus on innovation and patient impact. 

Looking ahead, the second half of the year promises even more exciting developments. We’re on track to reach key milestones that will further strengthen our position and bring new hope to patients around the world. 

At Ipsen, we’re not just executing on our strategy — we’re transforming lives. Because we believe that everyone deserves a life fully lived.